Two Sigma Advisers LP Has $1.06 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Two Sigma Advisers LP lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 86.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,976 shares of the biopharmaceutical company's stock after buying an additional 52,000 shares during the quarter. Two Sigma Advisers LP's holdings in Amicus Therapeutics were worth $1,055,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. KBC Group NV boosted its holdings in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the last quarter. R Squared Ltd purchased a new position in shares of Amicus Therapeutics during the fourth quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. boosted its holdings in Amicus Therapeutics by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock valued at $597,000 after acquiring an additional 6,314 shares during the period. Tempus Wealth Planning LLC bought a new stake in Amicus Therapeutics in the 4th quarter worth $259,000. Finally, Choreo LLC purchased a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $103,000.

Analyst Ratings Changes

Several brokerages recently weighed in on FOLD. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. The Goldman Sachs Group lowered their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. UBS Group upped their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Amicus Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Trading Down 2.6%

Shares of NASDAQ FOLD traded down $0.16 during mid-day trading on Wednesday, hitting $6.10. 4,522,170 shares of the company traded hands, compared to its average volume of 2,910,781. Amicus Therapeutics, Inc. has a 1 year low of $5.81 and a 1 year high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -33.89, a PEG ratio of 1.51 and a beta of 0.64. The business has a 50 day moving average of $6.69 and a two-hundred day moving average of $8.50.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.